Open AccessIn Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method
Author(s) -
Michael A. Pfaller,
L. Boyken,
Richard J. Hollis,
J. Kroeger,
S. A. Messer,
S. Tendolkar,
Daniel J. Diekema
Publication year - 2009
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01155-09
Subject(s) - anidulafungin , caspofungin , micafungin , broth microdilution , microbiology and biotechnology , biology , medicine , antifungal , voriconazole , antimicrobial , minimum inhibitory concentration
We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 526 isolates ofAspergillus spp. (64A. flavus , 391A. fumigatus , 46A. niger , and 25A. terreus isolates) collected from over 60 centers worldwide from 2001 through 2007. Susceptibility testing was performed according to the CLSI M38-A2 method. All three echinocandins—anidulafungin (50% minimum effective concentration [MEC50 ], 0.007 μg/ml; MEC90 , 0.015 μg/ml), caspofungin (MEC50 , 0.015 μg/ml; MEC90 , 0.03 μg/ml), and micafungin (MEC50 , 0.007 μg/ml; MEC90 , 0.015 μg/ml)—were very active againstAspergillus spp. More than 99% of all isolates were inhibited by ≤0.06 μg/ml of all three agents.